Albireo, An Ipsen Company
Clinical trials sponsored by Albireo, An Ipsen Company, explained in plain language.
A biopharmaceutical company focused on liver diseases, now part of Ipsen.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Could this pill help kids with biliary atresia skip a liver transplant?
Disease control CompletedThis Phase 3 study tests odevixibat, a daily pill, in 254 children with biliary atresia who recently had Kasai surgery. The goal is to see if the drug can prevent the need for a liver transplant or death. Children take either odevixibat or a placebo for up to 2 years, and researc…
Phase: PHASE3 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Promising long-term results for rare liver disease drug in kids
Disease control CompletedThis study looked at the long-term safety and effectiveness of a drug called A4250 (odevixibat) in 116 children with progressive familial intrahepatic cholestasis (PFIC), a rare liver disease. The children took the drug for up to 72 weeks. The study measured changes in bile acid …
Phase: PHASE3 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC